Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

Osmangazi Üniversitesi Tıp Fakültesi Göz Hastalıkları A.D., Eskişehir, Prof. Dr. Intravitreal pegaptanib received approval for the treatment of age related macular degeneration (ARMD) in USA and European Union based on strong efficacy and safety results. The VISION trial data have demonstrated its benefit irrespective of angiographic subgroup. Its safety by the selective targetting of VEGF₁₆₅ is a theoretical advantage while limited gain in visual acuity and slow resolution of subretinal fluid are the weak sides of pegaptanib therapy. Its use in ARMD therapy may be by combinations with other nonselective VEGF inhibitors or photodynamic therapy. Keywords : Intravitreal pegaptanib